304 results about "Staphylococcus epidermidis" patented technology

The present invention provides probe arrays and methods of using the same for concurrent and discriminable detection of multiple strains of different species. In one aspect, the probe arrays of the present invention are nucleic acid arrays comprising (1) a first group of probes, each of which is specific to a different respective strain of a first species; and (2) a second group of probes, each of which is specific to a different respective strain of a second species. In many embodiments, the nucleic acid arrays of the present invention further include a third group of probes, each of which is specific to a different strain of a third species. In one example, a nucleic acid array of the present invention includes probes for sequences selected from SEQ ID NOs: 1 to 18,598, and can discriminably detect different strains of Streptococcus pyogenes, Streptococcus agalactiae and Staphylococcus epidermidis.

A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections. Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated with Staphylococcus bacteria.

The subject matter of the present invention is a bacteria or mix of bacteria having an antagonistic activity with respect to stains of S. aureus, P. aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and / or Malassezia furfur as well as the use thereof in the treatment and / or prevention of infections or colonisations related to those pathogens. The invention pertains to care products containing one or more non-pathogenic antagonistic strains intended to prevent and / or treat infections or colonisations on skin, wounds, mucous membranes and appendages.

The invention relates to the technical field of fibers, in particular to a mite and mosquito-bite preventing underwear, sleepwear and home wear which is characterized by comprising the following processing steps of: preparing medical liquid; carrying out dyeing and printing and other pre-treatments on cottons or cotton blended fabrics; preparing bleaching and dyeing liquid; dyeing cloth; carrying out high temperature tentering; and processing so as to prepare the underwear, the sleepwear and the home wear. According to the invention, the fabrics provided by the invention have the obvious effects of mite preventing, mosquito preventing, anti-bacterium, deodorization, rot resistance, itching relieving, blood circulation invigoration and meridians activation and the like; the repellent rate of dust mite is as high as 99 percent; the repellent rate of mosquito is 95 percent; the repellent rate of termite is 95 percent; fabric-touching pathogens such as staphylococcus aureus, staphylococcus epidermidis, gonococcus and esherichia coli and the like can be completely killed; all efficacies of the fabrics still reach to over 97 percent after the fabrics are washed for 50 times; and the fabrics have the advantages of no irritation to skin, no anaphylactic reaction, no toxicity to the human body, comfort for wearing and can effectively prevent the infection of asthma and other diseases.

The invention belongs to the medical technical field and discloses the application of high-purity in the preparation of antibacterial medicine, antiviral medicine and other medicines. The invention proves the antipyretic, anti-inflammation, immunity enhancement, antibacterial and anti-virus effects of high-purity forsythiaside through the following experiments: (1) the experiment that high-purity forsythiaside has antipyretic effect on fever rats; (2) the experiment that high-purity forsythiaside inhibits xylene-induced mice ear edema, xylene-reduced capillary permeability of mice; (3) the experiment that high-purity forsythiaside increases carbon clearance ability of mice and increases the lymphocyte transformation rate; (4) the experiment that high-purity forsythiaside has vitro anti-influenza A type virus effect and in-vivo anti-respiratory syncytial virus effect; (5) the experiment that high-purity forsythiaside has vitro inhibition effects on beta-hemolytic streptococcus, staphylococcus aureus, streptococcus viridans and staphylococcus epidermidis.

Provided are: a skin-protecting agent and an external preparation for skin protection, which not only synergistically work in combination with a plant polysaccharide but also has an effect of promoting the production of glycerol derived from Staphylococcus epidermidis, which is a skin resident bacterium useful on the skin, and the production of antimicrobial peptides derived from skin epidermal keratinocytes and exhibits excellent effect of improving the touch feeling when applied to the skin. More specifically, the present invention provides a skin protective agent and an external preparationfor skin protection, which comprise a lactic acid bacterium belonging to the genus enterococcus.

The invention relates an air cleaner, solving the problem that the current air cleaners isn't disclosed the date of removing pneumococcus klebsiella and staphylococcus epidermidis and the date of effective degerming life, and the cleaning effect of current air cleaners is not good. The invention adopts the technical project that the silver particles below 100 nanometer are fixed on the surface of carrier to solve the problem.

A crystallized cefathiamidine is prepared from the cefathiamidine solution through controlling pH to 3.5-6.5, adding proper solvent until the solution becomes cloudy, controlling saturation procedureand crystal growth speed while adding said solvent, separating and drying. Its advantage is uniform granularity. It can be used to prepare the medicines for treating the infection of staphylococcus aureus, pneumoccus, enterococcus, streptococcus, etc.

The present application discloses antibodies directed to protein SE2232 (SesC) of Staphylococcus epidermis, and homologus proteins which are useful in preventing biofilm formation by said micro-organism. The antibodies can be used to coat medical devices which are inserted or implanted into the mammalian, preferably human body. Further these antibodies or vaccines comprising said proteins can be used to vaccinate subjects to prevent or treat natural occurring biofilm formation during infection. Also covered are medical devices coated with the antibody.

The invention provides a TiNiAg memory alloy with the antibacterial function and a preparation method thereof. The TiNiAg memory alloy contains 20%-80% of nickel, 0.1%-10% of silver and the balance of titanium by atomic percent. The alloy not only has good shape memory effect and superelasticity, but also has good matching of mechanical properties. Simultaneously, the alloy material has good corrosion resistance and biocompatibility in simulated body fluid, and cytotoxicity is in the same level of a TiNi alloy. In addition, the alloy material has a broad antimicrobial spectrum and can well inhibit Staphylococcus aureus, Escherichia coli, Staphylococcus epidermidis and other gram-negative and positive bacteria.

The present invention is based on the surprising antiseptic nature of chlorhexidine when combined with essential oils. It has been found that chlorhexidine, combined with an essential oil, is surprisingly effective at penetrating the skin surface and providing an antiseptic effect within the skin. It has also been found that a combination of chlorhexidine and eucalyptus oil is surprisingly effective as an antimicrobial against Staphylococcus epidermidis.

The invention relates to a 3-carbonyl-6-ethoxycarbonyl-thiazole pyrimidine compound and a synthesis method and application thereof. The compound has a right structure formula. The 3-carbonyl-6-ethoxycarbonyl-thiazole pyrimidine compound serving as an inhibiting agent of YyCG histidine kinase protein for a staphylococcus epidermidis signal transduction system has a novel structure, and the adopted method for preparing the compound is simple and easy to implement. The test results of the minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) show that the compound has excellent inhibitory action on the formation of a staphylococcal biological film and can effectively kill and wound the bacteria in the staphylococcal biological film.

Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG protein or its ligand binding A region are used to treat or prevent staphylococcal infection, and these methods can also be utilized to prevent the formation of infections on indwelling medical devices.

The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Several of these lead compounds were not toxic for mice at 200 mg / Kg doses administered over a period of three days.

The present invention relates to gene chip for detecting several kinds of common bacterial pathogens, and the gene chip includes solid carrier and oligonucleotide probe fixed on the carrier. The chip has up to 200 low density distributed sample points. The oligonucleotide detecting probe includes DNA' s selected from nucleotide sequences corresponding to the genomes of nine kinds of common bacterial pathogens, including Staphylococcus aureus, Staphylococcus epidermidis, bacillus pyocyaneus, colibacillus, etc. The said chip together with sample treating reagent, hybridizing reagent, color reagent and the specification constitutes the detection kit. The present invention has high detection efficiency.

The invention discloses preparation and application of recombinant plectasin. The method comprises designing plectasin gene according to preferred codons of Pichia pastoris, wherein possible nucleotide sequences of the plectasin gene are expressed in SEQ ID NO. 1, constructing recombinant expression vectors pPICPlectasin and recombinant genetic engineering bacteria Pichia pastoris X33pPICPlectasin (CGMCC NO. 3564), carrying out a high density fermentation process on the recombinant genetic engineering bacteria Pichia pastoris having a high expression level, wherein a total protein concentration of supernate from the high density fermentation process is 729 microgrammes per milliliter, dialyzing and freeze-drying the supernate, and orderly carrying out a gel filtration chromatography treatment and a reversed phase high performance liquid chromatogram treatment on the freeze-dried supernate to obtain high purity recombinant plectasin. The high purity recombinant plectasin is not hemolytic, has favorable PH stability, heat stability and anti-pepsin activity, and can inhibit effectively the growth of gram-positive pathogen Streptococcus pneumonia, staphylococcus aureus and staphylococcus epidermidis. Therefore, the high purity recombinant plectasin can be utilized for treating and preventing gram-positive bacterium and especially streptococcus and has potential antimicrobial drug development values.

The invention discloses antibacterial peptide, and belongs to the field of molecular biology. The antibacterial peptide has an amino acid sequence which is as shown in SEQ ID NO:2: Asn Trp Phe Ala Ile Thr Asn Trp Leu Trp Tyr Ile Lys Lys Lys Lys. The antibacterial peptide disclosed by the invention not only has an obvious inhibiting effect on gram negative bacteria, such as Escherichia coli, bacillus subtilis and staphylococcus epidermidis, and positive bacteria, but also has very low hemolytic activity and cytotoxicity, and the antibacterial peptide has good stability and high antibacterial activity, has an efficient broad-spectrum antibacterial effect and can be used as antibiotics substitutes.

The invention discloses an essential oil composition prepared by performing rectification and compounding processing on the raw materials comprising 4-terpilenol type tea-tree-oil and eucalyptus grandis x e.urophylla essential oil, and provides the formula, a preparation method and the composition content of the essential oil composition; and the composition has antibacterial insecticidal functions. A gas chromatography method is employed to determine the main content. The method is accurate, stable and easy to operate, is adaptable for industrial production demands, and can help to effectively control the quality of the essential oil composition. The essential oil composition has small toxicity, has different levels of inhibition effects on six pathogens comprising staphylococcus aureus, staphylococcus epidermidis, beta hemolytic streptococcus, escherichia coli, pseudomonas aeruginosa and candida albicans which can cause skin infection, and has antibacterial and insecticidal activities. The preparation method is reasonable and stable, short in production period, suitable for industrial production, and good in application prospect.

The invention discloses a compound heartleaf houttuynia herb bacteriostatic Chinese medicinal film and a preparation method thereof. The Chinese medicinal film consists of the following components in part by volume: 15 to 25 parts of chitosan, 5 to 100 parts of Chinese medicinal active ingredients and 1 to 2 parts of glycerin, wherein the Chinese medicinal active ingredients comprise the following raw materials in part by volume: 28 to 55 parts of heartleaf houttuynia herb extract, 20 to 40 parts of Mongolian dandelion herb extract and 5 to 15 parts of Chinese gall extract. The Chinese medicinal film has different degrees of bacteriostatic effects on staphylococcus aureus, staphylococcus epidermidis and Escherichia coli.

The invention relates to the technical field of medical detection, and in particular, relates to a primer and probe combination and a kit for detecting human pathogenic bacteria. The kit comprises theprimer and probe combination for detecting pseudomonas aeruginosa, escherichia coli, klebsiella pneumoniae, staphylococcus epidermidis, staphylococcus aureus, enterococcus faecium, human staphylococcus and acinetobacter baumannii. According to the kit, the primer and probe combination is adopted, multiple digital PCR is combined, the pathogenic bacteria types and the target nucleic acid copy number in the detection range can be rapidly and accurately identified, the detection method has high sensitivity, and positive detection of low-copy nucleic acid fragments of pathogenic bacteria is guaranteed; meanwhile, the variety of the pathogenic bacteria or the change of the copy number of the target nucleic acid fragment in the body of a pathogenic bacteria infected patient can be dynamically monitored, the treatment effect is assisted and evaluated in time, and reference is provided for optimization of a doctor clinical scheme.

The invention belongs to the field of examination of microorganisms, and relates to a method for quickly identifying bloodstream infection bacteria by a high-resolution fusion curve method. The method comprises the following steps of: performing smear gram staining on a blood culture positive culture flask to distinguish negative bacteria and positive bacteria; selectively amplifying different 16S fragments for the negative bacteria and the positive bacteria; and analyzing by the high-resolution fusion curve method. Common bloodstream infection pathogenic bacteria comprise staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, enterobacter cloacae, Serratia marcescens, Klebsiella oxytoca, acinetobacter lwoffii, enterobacter aerogenes, stenotrophomonas maltophilia and burkholderia cepacia. By the method, the common bloodstream infection pathogenic bacteria can be measured quickly, efficiently and accurately, so that strong evidences are provided and precious time is striven for subsequent treatment.

Provided is a Bifidobacterium animalis subsp. Lactis GFC-B09 strain and a cosmetic composition containing the same. The Bifidobacterium animalis subsp. Lactis GFC-B09 strain (Accession number: KCCM12263P) or a culture solution thereof has the ability to increase the amount of S. epidermidis, to degrade histamine, to inhibit allergies, to repair DNA, and to increase wrinkle resistance, skin whiteness, skin density, and skin elasticity, and thus can exhibit excellent effects as a cosmetic composition when contained as an active ingredient in a cosmetic base.

The invention discloses a composite bacteriostatic agent for reducing irritation. The composite bacteriostatic agent comprises a microcapsule, tea tree essential oil and a cream, wherein the microcapsule is prepared by taking salicylic acid as a core material and chitosan oligosaccharide as a wall material. Each gram of bacteriostatic agent contains 0.5-5mg of salicylic acid, 16-320mg of tea tree essential oil and the balance of cream. A chitosan oligosaccharide solution is used as a wall material solution, the salicylic acid is dissolved in an ethanol solution to form a core material solution, and then, the wall material solution and the core material solution are mixed, stirred and blended uniformly, sprayed and dried to obtain the composite bacteriostatic agent. The composite bacteriostatic agent prepared by the invention has a remarkable bacteriostatic effect on staphylococcus aureus, staphylococcus epidermidis and propionibacterium acnes, and achieves the same bacteriostatic effect even if the usage amount of the salicylic acid is reduced. The composite bacteriostatic agent has the advantages of simple preparation process, remarkable bacteriostatic effect, small usage amount, remarkable controlled / slow-release effect, short production period, low production cost and the like.

The invention provides compounds with a general formula (I) or (II), and acceptable salts or esters prepared from the compounds and inorganic acid or organic acid. In the general formula (I) or (II), Ar refers to aromatic heterocyclic hydrocarbyl or substituted aromatic heterocyclic hydrocarbyl; and X refers to hydrogen or fluorine. The compounds have a novel structure; 9-oxime hydroxyl of ketolide is connected with an aromatic heterocyclic hydrocarbon through a propargyl side chain; and the compounds are easy and convenient to synthesize and are suitable for industrial production. Moreover, the compounds have outstanding antibacterial activity on clinically common sensitive bacteria and drugfast bacteria, such as staphylococcus aureus, streptococcus pneumonia, streptococcus pyogenes, staphylococcus epidermidis and the like, can be independently used or serve as one of active ingredients to be mixed with other medicines to treat bacterial infection and the like in various formulations or medication ways. Correspondingly, the invention also provides a preparation method for the compounds, use of the compounds as anti-infective agents and corresponding medicinal compositions.

A protein isolated from Staphylococcus epidermidis having an approximate MW of 52 kD determined by SDS-PAGE and an N-terminal amino acid sequence (SEQ ID NO:1), and antigenic determinant-containing fragments of the protein, optionally coupled to an inert carrier or matrix, are disclosed. Disclosed are also a recombinant DNA molecule coding for the protein or the protein fragments; a vector comprising the DNA molecule or the corresponding RNA molecule; antibodies or antigen-binding peptides recognizing and specifically binding to the protein or protein fragment; use of the protein or protein fragment, or the vector, for the production of vaccines against Staphylococcal infections; use of the antibodies or antigen-binding peptides for the production of a medicament for passive immunization; a vaccine against Staphylococcal infections comprising the protein or protein fragment, or the vector, a medicament for passive immunization comprising the antibodies or antigen-binding peptides; and a method of prophylactic and / or therapeutic treatment of Staphylococcal infections.

The invention discloses a rapid detection method of blood pathogenic bacteria based on CE-SSCP (Capillary Electrophoresis-Single Strand Conformation Polymorphism). In the rapid detection method, specific to conserved regions of 16SrRNA genes of staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, staphylococcus epidermidis, klebsiella pneumoniae, enterococcus faecalis and streptococcus pneumoniae which are infected by blood, a corresponding PCR (Polymerase Chain Reaction) general primer is designed and subjected to fluorescence labeling, and then PCR is adopted to carry out amplification and electrophoresis detection on pathogenic bacteria in a blood sample, wherein the length of the designed general primer is suitable to the span of the amplification and has high complementary degree with the DNA of a pathogenic bacteria template in the blood sample to be tested, which enables an amplification product to have good specificity and favorable suitability to same kind of bacterium of different bacterial strains. The method has good repeatability and high sensitivity, can detect trace amount of the DNA of a pathogenic bacteria genome and is very suitable to wide application clinically.